| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $1,838,484 | 7 | 100 |
| Avelar Rui | See Remarks | 0 | $0 | 3 | $177,612 | $-177,612 |
| MOATAZEDI DAVID | See Remarks | 0 | $0 | 4 | $1.66M | $-1.66M |
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Over the last 12 months, insiders at Evolus, Inc. have bought $0 and sold $1.84M worth of Evolus, Inc. stock.
On average, over the past 5 years, insiders at Evolus, Inc. have bought $706,690 and sold $13.62M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,000 shares for transaction amount of $204,486 was made by Stewart Brady (director) on 2025‑08‑15.
| 2026-09-02 | Sale | MOATAZEDI DAVID | See Remarks | 105,108 0.1592% | $9.04 | $950,019 | -14.57% | |
| 2026-03-20 | Sale | MOATAZEDI DAVID | See Remarks | 13,669 0.0215% | $4.75 | $64,929 | +44.83% | |
| 2026-03-20 | Sale | Avelar Rui | See Remarks | 3,119 0.0049% | $4.75 | $14,815 | +44.83% | |
| 2026-03-17 | Sale | MOATAZEDI DAVID | See Remarks | 116,720 0.1786% | $4.89 | $570,562 | +36.66% | |
| 2026-03-17 | Sale | Avelar Rui | See Remarks | 29,996 0.0459% | $4.89 | $146,629 | +36.66% | |
| 2025-12-22 | Sale | Avelar Rui | See Remarks | 2,261 0.0035% | $7.15 | $16,168 | -11.40% | |
| 2025-12-22 | Sale | MOATAZEDI DAVID | See Remarks | 10,539 0.0162% | $7.15 | $75,361 | -11.40% | |
| 2025-08-22 | Sale | Yamagishi-Dressler Tomoko | Chief Marketing Officer | 5,722 0.0087% | $7.51 | $42,972 | -17.06% | |
| 2025-08-15 | Stewart Brady | director | 30,000 0.047% | $6.82 | $204,486 | -5.35% | ||
| 2025-06-16 | Sale | MOATAZEDI DAVID | See Remarks | 16,582 0.0255% | $9.89 | $164,054 | -34.74% | |
| 2025-06-13 | Sale | MOATAZEDI DAVID | See Remarks | 111,323 0.1748% | $10.05 | $1.12M | -34.54% | |
| 2025-06-09 | White Albert G III | director | 20,000 0.0304% | $9.45 | $189,000 | -32.64% | ||
| 2025-05-13 | Sale | Beaver Sandra | Chief Financial Officer | 6,494 0.01% | $10.02 | $65,070 | -34.65% | |
| 2025-05-12 | Sale | MOATAZEDI DAVID | See Remarks | 15,787 0.0242% | $9.87 | $155,756 | -33.67% | |
| 2025-05-12 | Sale | Avelar Rui | See Remarks | 3,385 0.0052% | $9.87 | $33,397 | -33.67% | |
| 2025-03-27 | Sale | MOATAZEDI DAVID | See Remarks | 6,251 0.01% | $12.40 | $77,512 | -42.89% | |
| 2025-03-18 | Sale | MOATAZEDI DAVID | See Remarks | 103,376 0.1623% | $13.26 | $1.37M | -46.69% | |
| 2025-03-18 | Sale | Avelar Rui | See Remarks | 27,904 0.0438% | $13.26 | $369,868 | -46.69% | |
| 2025-03-18 | Sale | Beaver Sandra | Chief Financial Officer | 8,996 0.0141% | $13.26 | $119,243 | -46.69% | |
| 2025-03-18 | Sale | Yamagishi-Dressler Tomoko | Chief Marketing Officer | 4,536 0.0071% | $13.26 | $60,125 | -46.69% |
| Medytox Inc. | 3381326 5.1193% | $24.92M | 15 | 9 | <0.0001% | |
| Malik Vikram | director | 246514 0.3732% | $1.82M | 4 | 7 | +1.4% |
| Jafar Michael M. | See Remarks | 174851 0.2647% | $1.29M | 1 | 1 | <0.0001% |
| Stewart Brady | director | 88629 0.1342% | $653,195.73 | 1 | 0 | <0.0001% |
| BLANK SIMONE | 54881 0.0831% | $404,472.97 | 3 | 0 | <0.0001% | |
| White Albert G III | director | 50378 0.0763% | $371,285.86 | 1 | 0 | <0.0001% |
| GILL DAVID N | director | 33964 0.0514% | $250,314.68 | 2 | 3 | +8.2% |
| Hau Bosun | director | 10040 0.0152% | $73,994.80 | 2 | 0 | <0.0001% |
| FARRELL PETER C | 10000 0.0151% | $73,700.00 | 1 | 0 | <0.0001% | |
| HAYMAN ROBERT | director | 10000 0.0151% | $73,700.00 | 3 | 0 | <0.0001% |
| Romine Kristine | director | 3450 0.0052% | $25,426.50 | 10 | 0 | <0.0001% |
$131,310,609 | 62 | 26.99% | $107.44M | |
$102,709,455 | 46 | 30.55% | $1.45B | |
$33,884,330 | 45 | 12.56% | $223.45M | |
Evolus, Inc. (EOLS) | $98,035,963 | 43 | -10.97% | $486.79M |
$11,542,910 | 40 | 56.19% | $1.07B |
| Increased Positions | 93 | +49.47% | 11M | +19.97% |
| Decreased Positions | 80 | -42.55% | 17M | -30.47% |
| New Positions | 41 | New | 7M | New |
| Sold Out Positions | 31 | Sold Out | 7M | Sold Out |
| Total Postitions | 201 | +6.91% | 49M | -10.5% |
| Nantahala Capital Management, Llc | $38,484.00 | 8.81% | 5.73M | +2M | +36.42% | 2025-09-30 |
| Tang Capital Management Llc | $36,881.00 | 8.44% | 5.49M | +490,900 | +9.82% | 2025-09-30 |
| Blackrock, Inc. | $30,083.00 | 6.89% | 4.48M | +292,635 | +6.99% | 2025-09-30 |
| Caligan Partners Lp | $27,814.00 | 6.37% | 4.14M | +796,973 | +23.85% | 2025-09-30 |
| Vanguard Group Inc | $23,042.00 | 5.28% | 3.43M | +110,693 | +3.34% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $17,678.00 | 4.05% | 2.63M | +195,115 | +8.01% | 2025-09-30 |
| Millennium Management Llc | $12,493.00 | 2.86% | 1.86M | +375,577 | +25.32% | 2025-09-30 |
| Stonepine Capital Management, Llc | $10,325.00 | 2.36% | 1.54M | +619,891 | +67.64% | 2025-09-30 |
| State Street Corp | $10,182.00 | 2.33% | 1.52M | +108,623 | +7.72% | 2025-09-30 |
| Eversept Partners, Lp | $9,913.00 | 2.27% | 1.48M | +304,798 | +26.04% | 2025-09-30 |